-
International Journal of Nanomedicine
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Clinical applications of azithromycin microspheres in respiratory tract infections
(2881) Views (706) Full article downloads
Authors: Francesco Blasi, Stefano Aliberti, Paolo Tarsia
Published Date January 2007
Volume 2007:2(4) Pages 551 - 559
DOI: http://dx.doi.org/10.2147/IJN.S
Francesco Blasi, Stefano Aliberti, Paolo Tarsia
Institute of Respiratory Diseases, University of Milan, IRCCS Fondazione Policlinico-Mangiagalli-Regina Elena Milano, Italy
Abstract: Few adequately designed clinical trials have addressed optimal treatment duration in lower respiratory tract infections. Drugs possessing favourable pharmacokinetic and pharmacodynamic profiles may obtain early bacterial eradication allowing shorter treatment duration. This may be associated with a number of advantages including reduced resistance induction, increased compliance, lesser adverse events, and cost containment. Recently, a novel 2.0 g single dose of azithromycin microspheres has been compared with 7-day levofloxacin 500 mg or extended release clarithromycin in over 400 patients with community-acquired pneumonia. Clinical cure and bacteriological eradication rates, hospitalizations, and deaths were similar between azithromycin and comparators. Azithromycin 2.0 g microspheres proved as effective as 7 days of levofloxacin 500 mg in acute exacerbation of chronic bronchitis patients across all degrees of obstruction severity. In both settings Azithromycin microspheres obtained clinical cure in most patients harbouring macrolide-resistant Streptococcus pneumoniae strains. The drug was well tolerated in clinical studies and in healthy volunteers with modest and transitory adverse events. An undoubted advantage of single-dose azithromycin administration is the facility in ensuring that patients complete their prescribed course of therapy. A further advantage of single-dose therapy is the potential for use as directly-observed therapy, which may be useful in specific clinical conditions.
Keywords: azithromycin microspheres, pneumonia, COPD exacerbations
Readers of this article also read:
Adverse effects of fullerenes on endothelial cells: Fullerenol C60(OH)24 induced tissue factor and ICAM-1 membrane expression and apoptosis in vitro
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Amino acid-responsive Crohn's disease: a case study
Amino acid management of Parkinson’s disease: a case study
Formulation and evaluation of Bacillus coagulans-loaded hypromellose mucoadhesive microspheres
Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Interested in being a peer-reviewer?
Click here to register.
- Display new articles on your site
Use our widget to show articles on your own site
- Applications of gold nanoparticles in cancer nanotechnology
- Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer
- Gold nanoparticles: From nanomedicine to nanosensing
- Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases




